Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

memo - Magazine of European Medical Oncology

Issue 4/2023

Content (18 Articles)

Hematology editorial

Editorial

Ewald Wöll

Pancreatic Cancer editorial

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

Gabriel Rinnerthaler

Trastuzumab editorial

HER2 in focus—gastric cancer

Aysegül Ilhan-Mutlu

Prostate Cancer editorial

Prostate cancer special—part 1

Shahrokh F. Shariat

Cancer Emergencies editorial

Supportive management

Christoph Minichsdorfer, PhD

Glioma short review

ASCO 2023: new treatment options in CNS tumors

Josef Pichler

Pancreatic Cancer short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

Patrick Reimann, Thomas Winder

Open Access Kidney Cancer short review

Renal cell carcinoma

Jasmin Spiegelberg

Open Access Hepatocellular Carcinoma short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Angela Djanani

Open Access Trastuzumab Deruxtecan short review

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Aysegül Ilhan-Mutlu, Ewald Wöll

Trastuzumab case report

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

Sophie Roider-Schur, Sybille Machat, Leopold Öhler

Prostate Cancer comment

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Isabel Heidegger, Andreas Pircher

Open Access Prostate Cancer short review

Focal therapy in intermediate- and high-risk prostate cancer

Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat

Open Access Prostate Cancer short review

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

Sazan Rasul, Stephan Korn

Open Access Filgrastim short review

Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors

Petar Popov

Open Access Erythropoietin short review

Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients

Ronald Heregger, Richard Greil

Hypercalcemia short review

Management of malignant hypercalcemia in cancer patients—a short review

Clemens Petrasch, Petra Marics, Thomas Spanberger

Chronic Lymphocytic Leukemia original report

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

Manal Atef, Layla M. Saleh, Noha Eisa, Sameh Shamaa

Sep 23
Issue: 3/2023
Dec 23
Issue: Special Issue 8/2023
A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits